CSIR Raman Research Fellowship 2019-2020 notification is out.

This issue covers the story of a  young vibrant personality who raised to success and fame in the healthcare sector, the space which is largely dominated by the male peers. As she ventured into the entrepreneurial road, she not only grabbed the investor's trust but became media's favourite. Attaining the feat of being a billionaire before turning 30 was after all a no minor feat! But the fairytale rise of Elizabeth Holmes’ Theranos soon came to a horrendous fall. Find out the truth behind its speculated fraud, revoking its California lab license and banning the charming young entrepreneur from the business for at least two years in this issue. 

Other articles to interest are “The DeepMind controversy- is patient data at risk”, article on “AI, Robotics and Biotech” , “Ebola sets for a scathing re-entry”, “Turning waste into wealth” and more.
 
Our utmost gratitude to Mr. Vijay G. Pande, Managing Director, Vijyoti and Mr. R.P Mishra, Director, Innovation LifeSciences for sparing their precious time and interacting with Biotecnika magazine.

The deadly wrath of Zika might soon be at rest and more treatments could be pouring in to cure it and more methods at its way to control its spread. It could be achieved now as the most gruelling task of decoding the entire structure of the virus has been achieved by a group of researchers from Purdue University. 

The issue not only covers how the virus structure was unveiled but also the proud moment of an Indian being the part of this extraordinary finding. 
Ms. Devika Sirohi, a PhD scholar at Purdue, was the youngest member of the team who decoded Zika virus structure. Read the exclusive coverage on this young scientist, the findings of the research and what it could hold in the future. 

Other features included in the issue are “Super 13: the world of X-men and superhumans is here”, “GMO special article: Would losing on GMO take a toll on environment, economies too?”, “Why are billionaires investing if BT has no scope?” and more.
 
Special thanks to Mr. Ketan Zota, Director, Zota Healthcare and Mr. Robert Balderas, VP, Market Development, BD Biosciences, USA who took out precious time from their busy schedule to interact with Biotecnika magazine.

There is no denying in the fact that the ‘women-force’ forms the most substantial and effective workforce, and that they have stood at par with the male counterparts at every levels and at every field. In life science sector too, they have not only busted the popular belief that entrepreneurship is a male dominated area but also proved their prowess beyond exceptional. Celebrating the success and opulence of women in the life science industry, we have picked out 10 such names that made it big in the industry and with much aplomb. However with the ever growing life science and biotech sector, the success stories are not limited to these 10 names but reaches far beyond.
 
Other stories to interest are “Storing Brain to computer- the unrealistic way!” which talks about the idea of being immortal by transferring brain to computer, “Monsanto- India spat and whether it would risk GM prevelance in the country”, “What Budget 2016 has to offer to the life science sector” and much more. Also read the conversation of Biotecnika magazine with Mr. Niven N Narain, CEO and Founder, Berg Heathcare.

The unchecked spread of virus created a situation of panic in major parts of the globe to an extent of a "Global health emergency" being declared by the WHO. "Zika", the miniature devil wrecked the lives of many especially infants who were being born with deformity called "microcephaly". While many linked it to Zika, there were also theories of it being spread by an experimental pesticide by Monsanto which was used in Brazil. Amidst the miseries, controversies, speculations and cures, Zika wrath has surely made an headline and we have covered the various aspects of Zika in this issue. 

More in this edition are the controversy around cultivation of GM mustards,  the affect on Indian exporters of mandate by the US government to manufacture APIs locally, a fun read on body parts that we no longer need  to name a few.

A special thanks to Dr. Shivendra Bajaj, Executive Director, ABLE-AG and to Mr. Amit Chopra, MD ThermoFisher India and Mr. Mark Field, CTO, ThermoFisher who interacted with us.

Being a BT professional in India is often speculated as the path towards struggle and why not- it is often surrounded by questions like will it pay me the best, does it offer enough pay hikes, do I have a job security and many more. But this new year might bring a smile to the BT professionals in India as the salary survey conducted by Mercer’s All Industries Total Remuneration says that it might witness the highest pay rise in the year 2016! Amidst the expectations of an increase in the base salaries of overall industries by 10.5%, life science domain would get lucky in terms of hike. The covers story speaks about the same which makes up for a must read. 

Other stories to interest are start-up scheme by Modi and how it could enhance biotech business in the country,  focusing on the talks of the science connoisseurs in the Indian National Congress held at Mysore which focuses on inventing in India, Samsung embracing biotech business and stepping into the lines of Google and much more.

Special thanks to Dr. Ramesh Raliya, Research Scientist, Nano Research facility, Washington University for interacting with Biotecnika magazine. The issue also covers an interaction with Mr. Ankur Parikh, Director, Industrial UV at Alfaa UV. Also read tete-a-tete with Mr. Mark Field, CTO and Mr. Amit Chopra, MD, ThermoFisher India at the inauguration of New Emerging Digital Technology Centre at Bangalore.

A very happy new year from the entire team of Biotecnika to its readers! While another year unfolds with its blank pages to be filled afresh, we hope for another action packed year. When it comes to biotechnology there were many stories that made headlines, but as the year was trending towards end, what caught everyone’s attention was the biggest fraud committed in the sector in 2015. Quoted as the “biotech biggest fraud” and the man involved in it as the “most hated man” in the entire globe, this new year special issue brings to you a story of success, greed and eventually a lesson that could be learnt from- story of Martin Shkreli and his unrealistic drug price hike and other frauds.
 
Many more stories that promises to keep readers engaged are “Captagon- Captivating ordinary to extraordinary!”, “Environmental chaos and biotech solution”, “Top 10 biotech/healthcare firms backed by Google and much  more. Special thanks to Dr. Maryam Sadeghi, Director, Digital Health Hub at Simon Fraser University and CEO & Founder at MetaOptima Technology Inc and Mr. Samartha Jain, CEO & Founder, Positive Biosciences for their precious time.
 
Grab your New Year special issue now!

Promoting women entrepreneurship, green solutions and development of eco-friendly techniques are on their agenda and are determined to make it a reality very soon! We are talking about the two women entrepreneurs Gayathri Thankachi and Aadra Chandra Mouli, who are currently leading the biotech company Aeka Biochemicals based in Kerala. They are focused on serving the society through Aeka while staying green in all ways.

Aeka manufactures biotechnological, biochemical & enzymatic products, chemical products or extracts of biological origin, and can be applied directly or indirectly in the development of products for relevant uses. In this issue read the story of Gayathri Thankachi and Aadra Chandra Mouli, the women entrepreneurs and founders of Aeka Biochem, who lead the first women owned biotech company. Other stories to grab your interest are Reversing aging, How Theranos, a successful biotech company rose and fell, Antibiotics and if they are nearing an end, Top 10 bioindustry trends for 2016 indicating the most importantly upcoming biotrends for the coming year and many more.

Special thanks to Dr. Amol Raut, CEO, GeneSupport; Shiladitya Sengupta and Ms. Dorothy Lou, Lead Business Development, Transcriptic (US) for their valuable contribution in bringing together their opinions on various verticals of bioindustry.

Grab our copy and be a part of the latest from the biotech industry! Subscribe now!

A successful road taken towards entrepeneurship in itself is a story to be inspired from and when the leader in the picture is a 30 year old Indian biotech entrepreneur, it could afford no miss even by a blink. In this issue read the story on Vivek Ramaswamy, an American based CEO who fetched world's largest IPO in biotech from an outcasted drug by GSK. Other stories to grab your interest are Artificial intelligence and if it has the potential to serve as a fairer option to drug discovery, Biosimilars and if India is competent enough in dealing with it, Top 10 pharma firms of 2015 based on their market capital and many more.

Special thanks to Dr. Geeta Shroff, the brain behind human stem cell line and Mr. Sunil Bhambarkar, President, Gattefosse India for their precious contribution in the making of their story, David Green, International biotech communication expert and Dr. Shivendra Bajaj, Executive Director ABLE AG for throwing an insight on GM technology.

It has been two successful years since Biotecnika magazine has taken stage and after traversing for two years, our ardor to serve the biotech industry has just doubled. With this edition, we celebrate the second anniversary of the magazine by highlighting the dedicated support to the industry, initiatives to promote the sector, looking at flaws for the betterment of the sector and much more. With this in mind, Biotecnika once again covers the topic that needs to be looked upon from a common man’s perspective.

As part of the cover feature, we have Dr. VA Shiva Ayyadurai in an exclusive interview with Biotecnika Magazine. The biotech industry was much appalled when the proclamations by Dr.VA Shiva about the rampant corruption inside the gates of CSIR hit the news-stands. He was in and out of CSIR within 5 months of his hiring, as his report claims of underlying bureaucracy inside the organization, questioning the credibility of CSIR. Listen to Dr Shiva himself as he uncovers the complete story in this issue.

Also, the interest levels reach an acme as we have on board Dr. Sergio Canavero, the first person behind the human head transplant initiative. Do not miss an exclusive feature on Prof. Canavero as the professor interacted with Biotecnika magazine, as part of its second anniversary special issue.
 
While October issue is all about celebrating the second anniversary, we included features in the order of 24 issues-24 milestones, Digital India's impact on healthcare, Is polio staging a comeback?' and our ardent support to GM technology.
 
This anniversary, grab our copy and be a part of the latest from the biotech industry! Subscribe now!

While the government is too keen on implementing DNA Profiling Bill in the upcoming Parliamentary sessions, not everybody seem to be convinced with the much controversial bill, and why not? The Bill raises some serious concerns such as how far is the data secured? Would the DNA bank assure no infringement with the privacy of the data? Are strong regulatory bodies set in place to oversee the Bill and much more? The current issue of Biotecnika magazine covers the complete gist of the DNA Profiling Bill 2015- a must have & read!

Apart from this also read topics to interest the human ingenuity such as Super human genes, Cloud Computing, Top 7 Bioprinting breakthroughs of 2015”, tete-a-tete with Mr. Robert Nass, VP, Quality and Regulatory Management, Merck, coverage of inauguration ceremony of Thermo Fisher’s Technology Development Centre and a lot more! Grab your copy now to keep yourself at par with the industry updates.

Controversies hovering food industry are many, but one recent entry has pushed the industry into a precarious situation. The most favourite breakfast snack, Maggi, was banned by the Indian authorities, post which, people are beginning to doubt every packed food on the grocery store shelf. The issue has triggered a fear and also fury among the loyal bunch of consumers. As Nestle was pointed fingers at, there were also questions raised on the authenticity of the food quality analysis as carried out by the India Quality Control Analysts. Trying to analyse whether the brand was truly a killer or did it just mistakenly land into trouble, forms the background for our August issue cover feature titled, “Maggi: Silent killer brand or silently killed?”
 
Moving along, other features to interest you include CRO market, Top 7 CRO companies in emerging markets, Can GMOs offer solace to environmental crisis, and Surging insulin market. Also featured are the interviews with Dr. Amar Desai, Research associate at Case Western Reserve and also one of the research team members behind ‘Tissue regeneration drug’ and Mr. Ambuj Jain, India General Manager at Cambridge Consultants. Do not miss on what they had to say on the Indian bioresearch and pharma industry. Grab your copy now!

Along with the advent in technology that biotechnology has favoured to mankind, in rare cases there have been findings that could not go down well with people. GMOs are one such overly criticized technology which has received more suspicion than praises. In a false propaganda against GM crops, myths tend to weigh more than truth about it- for which media to a great extend could be blamed. With exponentially increasing population that could soon be followed by a shortage of food worldwide, GM technology could actually prove to be a boon, albeit anti GMO NGOs stop opposing. July cover features the same under the title “It’s time to prosecute anti-GMO NGOs- Combating false propaganda against GMO companies”.
 
Other stories to keep the interest up are “How to start a company in biotech”, “Will you get your genome sequenced- a global picture”, ‘Top 10 employers in biotechnology” and much more. Also featured are the talks with industry stalwart- Mr. Sumit Mitra, Global Marketing Manager, MolBio Diagnostics and Mr. G.S Krishnan, Regional President, Novozymes. What are you waiting for; grab your copy today to get new insights into the industry with Biotecnika magazine!

EditorBiotechnology sector is quite infamously famous for often receiv-ing the new comers into the industry quite coldly. Be it in terms of infrastructure, getting required approvals or even fetching investors, a bio-preneur’s tale has many villains to overcome before they could actually celebrate a success story. The June issue is dedicated to all the start ups in the industry who have tried hard to make a mark and to those who are still in the rising. The cover story revolves around the ‘hide and seek’ between biotech start ups and the investors and how compatible do they stand out compared to other sectors. Though biotech sector stays ambitious in terms of reaching a top spot in the charts but do we have enough opportunities for its people? We talk about the profit, but is there patience to wait for the returns? Quite sadly, no. Investors, who are mostly in a jiffy of looking for short term benefits often neglect on the huge profits that biotech could bring. There are a lot of strategies and improvements which if adopted could drastically change the scenario. Although in bits and pieces, we are heading towards that layout which is supportive of bio-preneur taking its step smoothly into the sector. Give a definite read to this biotech entrepreneur and investor relationship existing in India in the ‘BT start up special’ issue.

The Indian biotech sector faced a major turn of events when Daiichi Sankyo, Japanese firm whose hide and seek with Indian drug company Ranbaxy came to an end as it decided to sell off its entire holding of  Sun Pharmaceutical Industries and exit Indian pharma sector after a struggle of eight years. Why it had to offload Ranbaxy and what is in store with the company’s future businesses, find out in Biotecnika magazine’s May 2015 issue. Other stories to keep reader’s interest intact are “India succumbs to H1N1”, “Are we amid biotech bubble”, “Is it time to kill your R&D project?” and much more. Biotecnika bureau had a chance to interact with Ms. Anu Acharya, CEO, Mapmygenome on her entrepreneurial voyage and Dr. Anurag Mathur, Lead author, “Heart-on-chip” on his recent research. Grab your copy to find out what they had to say!

The surge in technology has made our lives easy in every form and its contribution towards improving healthcare is surely commendable. With an increasing trend in healthcare apps, Apple Inc. has taken a step forward and has brought in a concept of ResearchKit which has nested apps for various diseases such as asthma, cardiovascular ailments, Parkinson and much more. It allows its users to conduct tests and take part in studies hence claiming to revolutionize the way data is generated for clinical studies. Will Apple ResearchKit be a big hit? Read Biotecnika April issue to find out more on it. The issue also covers topics to interest such as “Top 10 biotech spenders”, “Budget review 2015”, “Increasing support for GM crops and much more” . Also read interview coverage of Mr. Neeraj Kathuria, Chief Manager, IKP – BIRAC Regional Innovation Centre and Ms. Maggie Massam, Head, Business development, Clinical Practice Research, Data Link, UK at BioAsia 2015. Grab your copy now!

Budget 2015, new government and newer hopes. As a new financial year is all set to begin, the budget is looked upon with expectations from all spectrums. Amidst a plethora of hopes, would the biotech sector, which is on its way of embarking a new zenith, receive equal attention as others? Covering thoughts and expectations from various industry patrons on the same, we have carved out our cover story as “Budget 2015: Would the country’s CFO endorse Biotech sector?” The other stories to interest our readers are the updates and interviews from the likes of Mr.Jupally Krishna Rao, Minister of Industries and Commerce, Telangana, Dr. Mak Jawadekar, former R&D Director, Pfizer, Dr. CSN Murthy, CEO, Aurigene, Founder of start-up, eKincare from BioAsia 2015 held in February, “Top 7 Indian serial entrepreneurs”, a contribution by Novozyme “Re-think tomorrow with fuel from wastes” and much more. Grab the copy now and stay updated with the leading magazine of bioscience sector.

With Modi taking over the helm of the country, a string of hopes came attached with it. And with expectations flowing in for improvement in all the sectors, dearth in biotechnology sector remains the most awaited one to be addressed. Will the change in strategies and policies bring about the desired change in the sector? Will ‘Modi’nomic strategies be able to modify biotech sector? Read along with the February issue of Biotecnika magazine to have a look on the same. Various other latest happening of the bioscience world are covered under the headings “Ebola Outrage, is a cure round the corner?”, “Could artificial womb bring the next big technological revolution?”, a write-up by Novozymes on their Bioagricultural aspect and much more. The issue would have been incomplete without the precious support extended by Mr. Ramesh Swaminthan, CFO, Lupin. So, wait no more and grab your copy to stay updated with the latest industry trends.

With New Year comes new hope and expectations to upbeat the last year achievements and set newer targets for the days ahead. The one sector where the professionals strive for a hopeful future is Indian Biotech Industry. Infamously famous for unsatisfactory growth and peanut salaries, we wish this year brings a bunch of reasons to celebrate. Carving our cover story around the salary structure of a biotech professional this New Year, the issue offers a story on “Salary Special” and covers every element to decide “Who pays you the best in Biotech sector”. To further keep the interest intact, we have penned down articles from various verticals of bioscience domain such as “M&A- hurting or helping the industry”, “Google enters sequencing space”, “Will Modi’s Make in India change the fate of GM crops” and much more. The issue would have been incomplete without the gracious support from Dr. Anand, CEO, Bugworks and Titan Biotech who helped us to have an insight into the biotech industry and rest the curiosity of readers at peace. Grab your copy this New Year to get a fresh insight on biotech sector!

When the world is unassertive of advocating the usage of gene modifying technology, the world’s most populous country has stepped its foot forward in promoting GM food through all forms of media. While most of the developed countries still avert the usage of GMO’s, the step taken by China is quite commendable. This issue we have weaved our cover story around the same talking about “GM crops-Promotion vs. Relegation”. To interest our readers further, the issue also features “Eating Chicken or Antibiotics”, “GM labeling- is it our right to know?”, “Google further leaps into bioresearch” and much more. We would like to mention special thanks to Dr. Surinder Kher, CEO, Ecron Acunova and Mr. Jhenkar Dixit, CEO, GridOctane for their time and support. The issue also features Proteomics Lab inauguration by Thermo Fisher Scientific in the BT capital of India. Don’t let the best from bioscience sector go amiss. Grab your copy now!

With newer government came newer policies and hence newer hopes. One among those is the recent 'Make in India' initiative by Modi government. Emphasizing on attracting investors and hence improving job opportunity, it raises hope on dealing the lacuna that biotech sector faces, particularly the dearth in investments. The current issue of Biotecnika magazine analyses if Make in India would prove to be a stylish attempt to attract investments to BT sector? The other features to interest readers are 'Imminent second green revolution', 'CO2 to plastics- GE microbes answering global pollution', 'Delaying aging- an answer to delaying diseases?' and many more. Also see the feature covering Titan Biotech and Siro Clinfarm. With  much more to acquaint yourself with, wait no more and grab your copy now!

Biotecnika Magazine celebrates its first anniversary! In this festive season, as we celebrate our successful one year, catering to thousands of readers from bio community, we hope to improve upon the best further as well! We express our gratitude to our readers and mentors for all their appreciation and support. The cover feature of October issue details on how IT majors have been backing biotech industry and proving to be a ray of hope for biotech sector. With Google, SAP, Infosys and more IT giants extending their funding and support to biotechnology, the future of the industry definitely stands at a better place. An opportunity to interact with Novozyme Regional President, GS Krishnan; Dr. Jagadish Mittur from KBITS and New Horizon Group of Institutions and include excerpts from respective interviews, has been a valuable addition. To further interest the readers, the issue offers articles titled; “The battle to be BT capital,” “Recalling the exemption in service tax” and “Is the road to cancer heading nowhere?” Much more awaits! Grab your Anniversary Special Copy and Stay Updated!

When the wrath of deadly Ebola is showing its heinous side by causing a global pandemic and silently taking a toll on population across West African countries, finding a full stop to this problem is what scientists all across the globe are striving for. Biotechnology which has been the answer to many such unforeseen hurdles in the past is being looked upon with high expectations and why not! It has the potential to sway away many major problems. Biotecnika's September issue talks about the same and chalks out, 'If biotech biggies would churn out a remedy soon?' Other topics to interest our readers are 'The battle with HIV--when will we win?', Ban on GMO trials...where is the road taking us?' and much more..The issue also interacted with biotech big names such as Biocon Academy, Stempeutics and Sigma Aldrich to know the industry better. Wait no more and grab your copy of Biotecnika magazine now!

While transitions are utmost necessity of life, is biotech sector witnessing transition at a same pace? Are the expectations from bio-community near fulfillment? Though the roadmap to a perfect biotech culture is far away, the budget allocation for biotech does keep our hopes intact. Featuring the same, the cover story of this issue details on how the budget allocation has been received by the bio community and analyzes ‘Did Modi’s budget quench the thirst of BT sector?’ Other topics to interest our readers are ‘The bionic brain-boon to paralyses’, ‘Genetic identity- to be kept under wraps or unconcealed?’, ‘Bio fortified food’ and so on. That’s not all as the readers get to know industry giants Mr.V.S Reddy, MD, British Biologicals, Ms.Shobha V., Coonexios Life Sciences and Mrs. Mirella Marlow, Programme  Director, NICE, UK.  Wait no more and grab your copy of Biotecnika magazine now!

Academia, believed to be the backbone of a successful career, holds to be a pertinent fit for a bloom in biotech sector. A recipe of perfect mix between the subjective and practical knowledge, biotechnology demands nothing short of a \'perfectly\' equipped manpower for it\'s labs. But are Indian universities on the right track to make such impeccable biotech professionals? July issue covers the complete analysis of \'Is Biotech Academia Going the Right Way? to know what are the pluses and minuses of these universities. Other topics to interest our readers are the very controversial subjects such as \'Contemplating 3 Parent baby Procedure\', \'Futuristic Biotechnology-Fear or Favor?\' etc. It also brings the industry close by interviewing the ingenious personalities from Waters, Thermo Fisher Scientific, GVK and Manipal University. So what are you waiting for? Hop on to grab your copy of Biotecnika magazine to get a complete insight into the biotech world...

Media hypes that can make even the most insignificant junk of a story to a national issue has all the powers to help people form their opinions. Biotechnology being the most controversial yet a significant subjects on the timeline, needs media to be a cupid connecting the masses with science. But is the media obligating towards all the positive aspects? The June issue of Biotecnika magazine covers the different moods of media towards biotechnology under the title \'Is biotech industry facing media bias..? Who do we believe!?\' Retaining the soaring temperature of interests, the issue has \'Patents on seeds and GMOs..Resist or recognize their way into agriculture?\', \'Pfizer & AstraZeneca ..Duo dancing a mega deal\' and \'Indian Intellectual policies..time to turn the corners?\' and much more..Also the interview of Dr. Shekhar Mande, Director, NCCS gives an insight into the bridge that connects industry to academia. Grab a copy of magazine right away to rejuvenate your biotech interests.

To pump up the election fever that India is inundated with, Biotecnika Magazine with this issue adds the biotechnological aspect to the much awaited and anticipated elections. With the parties contesting to win the seats, will it do any good to the blooming biotech and pharma field? Would the manifestos promising the growth, stand out this time? Analysing this and much more, the cover story has all the elements to indulge in for. What\'s more? The magazine offers the readers a look onto the war between Patenters and Infringers that has made a headline recently, the major move of Ranbaxy being bought by Sun Pharma, How Biotech can manage and salvage the waste and much more.. To retain the interests, interview of the Nobel Laureate Dr. Thomas Sudhoff,  Mitra Biotech\'s President and CEO and that of Biozeen\'s Executive Director does the needful... Grab your copy of the magazine to avail the best of biotech industry...

The intensifying eye of FDA on the Indian units of many pharmaceutical and biotech companies has raised many eyebrows on the issue striving to figure out who is correct and who is not. The current issue talks about the same,analyzing and viewing the point of views of both the parties. Apart from the intriguing cover, the issue also includes the wonders of biotechnology such as \'Bio printing\' which assures to be the biopromise of the future. To make the interest of the readers it coves various other aspects of biotech world such as \'Criticism vs Biotech progress\', \' Bioregulators..are you listeing?\' etc. To add the flavor to the coming elections, the views and ideas of political biggies on biotechnology has been potrayed in \'with election on edge..what politicians pledge\'? This and much more awaits you in the April issue of Biotecnika magazine.Wait no more and subscribe to Biotecnika Magazine now...

When the world goes wary with Information technology, biotechnology is all set to steal the show and doing the rounds as perceived by experts. This issue brings in an insight into the persisting scenario in and around IT and BT. Whether BT can match IT is the heated question right now and whether it can do all the wonders that IT did to India is the most awaited answer. Intriguing the reader throughout, this issue offers you the most debatable and high on the spot issues such as \'Patent wars\' and whether \'Recycling is healing or hurting the environment\'. To interest our readers from core research, \'Nanotechnology..A walk into the future and the \'Changing dynamics of Biosupplier industry does the needful. The drawbacks of the current biotechnology scenario in India is crafted out neatly in \'Where we fell short...In our quest to follow the best\'. Keeping yourself updated about the news and the happenings of the bio-world, March issue has every flavor to offer.

This issue highlights fiction with a flight of Bio-fantasy and Cover Story of Emerging Asia-all slated to make a history in biotech world.

December 2018

June 2016

May 2016

April 2016

March 2016

February 2016

January 2016

December 2015

November 2015

October 2015

September 2015

August 2015

July 2015

June 2015

May 2015

April 2015

The essential guide to all the news in biotechnology industry & Academia run by India's Most popular Biotechnology Portal www.biotecnika.org. BioTecNika has access to world’s most influential Biotech entrepreneurs, Businesses and institutions. The magazine showcases all this via exclusive features that are insightful, informative and presented with style. 

Distinguished by its indepth analysis and latest information, BioTecNika has been an indispensable part of life of Biotechies for over 8+ years. Our well-heeled readership shape opinions and trends in India and across the region. This affluent and influential group is almost impossible to reach - except through the pages of BioTecNika

1. お客様は、Magzter.com、アプリケーション、およびそのサービスの使用は単独でご自身の責任で行うことに同意します。 Magzter.com、その関連会社、従業員、サードパーティのコンテンツ プロバイダーは、サービスが完全に中断されないこと、エラーがないこと、不正行為に対して確実であることを保証しません。また、Web サイトや製品が期待または約束したとおりの正確な結果が得られることも保証しません。

11. サービスおよびすべての出版物は、「現状のまま」および「入手可能な状態」で提供されます。 MAGZTER、その関連会社、サプライヤー、ライセンサーおよび代理店は、明示的か黙示的かを問わず、商品性、特定目的への適合性、および権利侵害の非侵害に関する黙示的な保証を含むがこれらに限定されない、あらゆる種類の保証を明示的に否認します。上記を制限することなく、MAGZTER もその関連会社、サプライヤー、ライセンサー、代理店も、(I) サービスがお客様の要件を満たすこと、(II) サービスが中断されず、タイムリーに、安全に、またはエラーが発生しないことを保証しません。 III) サービスの使用から得られる情報、または出版物に含まれる情報が正確または信頼できるものである、または (IV) 出版物またはサービスの品質がお客様の期待に応えるものであること。信頼できるインターネット接続とデバイスの取得と維持については、お客様が単独で責任を負います。 MAGZTER は、お客様がコンテンツをダウンロードできないことについては責任を負いません。ダウンロードまたはサービスの使用を通じて取得したマテリアルは、お客様自身の裁量とリスクで行われ、かかるマテリアルのダウンロードに起因するコンピューター システムまたはモバイル デバイスへの損害またはデータの損失については、お客様が単独で責任を負うものとします。口頭か書面かを問わず、お客様が magzter から、またはサービスを通じて、またはサービスから得たアドバイスや情報は、いかなる保証も生じません。

2.お客様は、その情報を真実、正確、最新かつ完全なものに保つために維持し、速やかに更新するものとします。あなたは、自分のアカウントとパスワードの機密性を維持し、自分のコンピュータへのアクセスを制限する責任を負い、すべてのコンテンツとサービスの選択と使用を含む、自分のアカウントで行われるすべての活動に対する責任を受け入れることに同意します。

3. いかなる場合においても、Magzter.com、ウェブサイトおよびアプリケーション上のコンテンツの作成、制作、配布に関与する個人、団体、第三者は、契約上または法的責任を負いません。 Magzter.com の使用中または使用中にお客様に発生した直接的、間接的、付随的、特別、および結果的。 Web サイトに登録するか、アプリケーションをダウンロードすることにより、このセクションに記載されている規定が Web サイトおよびアプリケーションのすべての使用およびコンテンツに適用されることに同意するものとします。

3. Magzter からの事前の書面または許可がない限り、ここに公開されているものはすべて Magzter またはそのライセンサーの専有財産であるため、Magzter から取得したコンテンツを変更、コピー、配布、販売してはなりません。このような不正使用は、著作権法や商標法を含む適用法に違反する可能性があるため、Magzter はこれらを厳しく禁止し、そのような違法行為が証明または検出された場合は、アクセスとアカウントを停止します。また、これらの不正行為によって生じた損害についても責任を負う必要があります。出版物の法的所有者が許可する場合を除き、お客様は、サービスを通じてアクセスした出版物をダウンロードすることによって所有権を取得しないことを承認するものとします。著作権法で明示的に要求されている場合、またはサービスの機能によって許可されている場合を除き、変更、リバース エンジニアリング、公開、送信、表示、譲渡または販売への参加、派生作品の作成、またはいかなる形であっても商業的に利用または提供することはできません。 Magzter およびかかるコンテンツの所有者の明示的な許可なしに、アプリのコンテンツ、出版物、またはそれらの一部を第三者に提供すること。当社は、明示的か黙示的かを問わず、Magzter または Magzter のライセンサーの知的財産に対するライセンスを付与しません。

5. あなたは、Magzter.com が他のユーザーや第三者、またはそのコンテンツのいかなる種類の中傷的、攻撃的、または違法な行為に対して責任を負わないこと、および前述の行為による傷害のリスクは完全にあなたにあることを特に認めます。

8. Magzter は、お客様が本利用規約および Magzter が定めるその他の運用規則に準拠しているかどうかを判断する目的で、お客様が公開および入力したコンテンツを監視するすべての権利を留保します。 Magzter は、コンテンツについて決定を下し、独自の意志で削除する権利を有します。

9. Magzter は出版物の販売代理店であり発行者ではないため、Magzter は雑誌に掲載されている意見、アドバイス、声明、サービス、オファーなどを含むコンテンツに対する編集管理を行いません。したがって、Magzter は、そこで提供される情報や事実、または公式の資格に従って行動する Magzter の認定従業員以外の者がサービスを通じて利用できる情報や事実の正確性や信頼性について責任を負いません。したがって、当社には出版物に対する編集上の管理権がありません。本サービスが提供する出版物で行われた意見、アドバイス、声明、サービス、オファー、または第三者によって表明または利用可能にされたその他の情報またはコンテンツは、それぞれの著者または出版社のものであり、第三者のものではありません。マグザー。 Magzter は、サービスを通じてまたは出版物から得た情報への信頼によって生じた損失または損害に対して責任を負いません。本サービスには、他のインターネット サイトおよびサードパーティのリソースへのリンクが含まれている場合がありますが、Magzter は、そのようなリンクされたサイトで利用可能な通信またはマテリアルについては一切の責任を負いません。これらのリンクは便宜のためにのみ提供されています。サードパーティのサイトにアクセスしたり、サードパーティのサイトを通じて注文したりするときに適用される利用規約を理解するのは、お客様自身の責任です。

不快なコンテンツの詳細（プラットフォーム上のリンクを含む）

お気に入りの作品をダウンロードすれば、いつでもどこでもオフラインで読むことができます

愛する人に Magzter ギフト カードをすぐに贈り、何千ものベストセラー タイトルの中からお気に入りの雑誌や新聞を自由に読めるようにしましょう。

Gift your loved ones with a Magzter Gift Card instantly and give them the freedom to read their favorite magazines from thousands of best-selling titles.

{{magCount}}冊の人気のインターナショナル雑誌からお気に入りの雑誌を自由に選べるMagzterギフトカードを、大切な人に今すぐ贈りましょう。

Girish Ramdas は、世界的なデジタル出版ビジネスで話題を呼んでいる、ニューヨークを拠点とする新興企業 Magzter の共同創設者兼 CEO です。 Magzter は 2011 年のサービス開始以来、150 か国以上から 9,000 万人のユーザーを獲得しており、世界中の 4,500 以上の出版社から数千冊の雑誌、新聞、書籍が提供されています。彼は、印刷物、モバイル、Web 開発を含むクロスプラットフォーム出版において 25 年以上の経験があります。この期間中、彼は 3 つの新興企業を共同設立し、経営して成功を収めてきました。彼は雑誌社のデジタル化を可能にし、デジタル世界でコンテンツの収益化を支援してきました。ギリッシュは、オンライン、モバイル、出版エコシステムにおける深い業界経験により、世界中のプラットフォームにわたるデジタル コンテンツの取得、マーケティング、収益化の専門家となっています。

当社のプラットフォーム上で不快なコンテンツに遭遇した場合、当社はお客様の懸念に対処するために苦情救済ポリシーを導入しました。

Magzter Inc. (「当社」、「当社」、「当社」) は、お客様がご自身の個人情報がどのように使用および共有されるかについて関心を持っていることを承知しています。当社のプライバシー慣行の詳細については、次のプライバシー ポリシー(「ポリシー」) をお読みください。当社が運営するウェブサイトおよびそのサブドメインのいずれかにアクセスするか、当社のモバイル アプリケーションやその他のコンテンツ配信方法(総称して「サービス」) を使用することにより、概要が説明されている慣行およびポリシーに同意したことになります。本ポリシーに記載されており、お客様は、当社がお客様の情報を以下の方法で収集、使用、共有することに同意するものとします。

Magzter Inc. は、世界最大かつ急速に成長しているセルフサービスのクロスプラットフォーム デジタル ニューススタンドで、2011 年の創業以来 9,000 万人を超えるユーザーがおり、40 以上のカテゴリ、60 以上の言語にわたる数千の雑誌や新聞を扱っています。ニューヨークに本社を置く Magzter は、アムステルダム、ロンドン、メキシコシティ、チェンナイ、ムンバイ、ニューデリー、バンガロール、シンガポールに現地拠点を置いており、間もなく他の国にも拡大する予定です。 2011 年 6 月に世界的起業家であるギリッシュ ラムダス氏とビジェイ ラダクリシュナン氏によって設立された Magzter は、世界中の雑誌や新聞の出版社が自社のタイトルのデジタル版を作成し、世界中の消費者に配信できるようにします。

Magzter は、ユーザーに安全なプラットフォームを提供することに尽力しています。 Magzter は、パブリッシャーがコンテンツを配布するためのプラットフォームにすぎないことに注意してください。当社は、当社のプラットフォームで公開されるコンテンツを管理または推奨しません。当社は、発行者の行動またはそのコンテンツに対して責任を負いません。

Magzter は、コンテンツまたはコンテンツの一部が権利を侵害したために損害を被った、または費用が発生した当事者を補償する責任を負いません。 Magzter は、第三者の権利を侵害するコンテンツまたはコンテンツの一部に起因する権利侵害について、民事裁判所で法的措置を講じる責任を負いません。

Magzter は、Magzter GOLD と呼ばれる世界最大の「読み放題」サブスクリプション サービスを提供しています。これにより、デジタル読者は月額サブスクリプション料金で 9,000 以上の雑誌や新聞に無制限にアクセスできます。 Magzter はまた、アプリ向けの革新的な ezRead 2.0 機能により、世界最大の記事数を誇ります。これにより、スマートフォンや小さな画面のモバイル ユーザーは、本来の楽しみ方で雑誌コンテンツを楽しむことができます。読みやすく、素晴らしいビデオと高解像度の写真が付いています。

名前

Magzterでのコンテンツ発行に関するサポートが必要は場合は、このフォームに記入してください

 Magzter に入社する前は、Dot Com Infoway (DCI) および Galatta Media の社長を務めていました。彼の任務には、戦略的マーケティング、パートナーシップ開発、コンテンツの世界的な収益化が含まれていました。 DCI は、2000 年には 3 人だった小さなチームから、2011 年には 300 人にまで成長し、世界中のクライアント向けに Web、ソフトウェア、アプリの開発を手がけていました。

Magzterの開始以来、お客様に最高のニューススタンドテクノロジーとサービスを提供するため、世界各国の組織や機関と提携することに尽力してきました。雑誌の購読を顧客に提供したい場合や単に詳細に興味がある場合など、お気軽にお問い合わせください。Magzterはお客様のビジネスの成長を支援いたします。お問い合わせ内容について、以下の質問票にご記入ください：

{{trailText}}無料でお試しください

{{trialPackText}}無料でお試しください

 DMCA では、元の DMCA 通知を提出した当事者が反対通知のコピーを受け取ってから 10 営業日以内にお客様に対して訴訟を起こさない場合、当社は削除されたコンテンツを復元することができます。

このポリシーは、お客様がサービスにアクセスする際に当社が収集する、個人を特定できる情報(「個人情報」) およびお客様およびお客様のコンピューターまたはデバイスに関するその他の情報の当社の取り扱いを対象としています。以下で詳しく説明するように、当社はお客様から個人情報を収集することがあります。当社はこの個人情報を、当社の製品、サービス、コンテンツ、広告をパーソナライズ、提供、改善するため、またお客様がユーザー アカウントとプロフィールを設定し、お客様に連絡し、特定の製品やサービスに対するお客様のリクエストを満たし、お客様によるサービスの使用状況を分析するため。場合によっては、当社は一部の個人情報を第三者と共有する場合もありますが、これはポイント 4 に記載されているとおりに限られます。

このタイトルは Magzter GOLD サブスクリプションに含まれています

コンテンツの品質を分析し、パブリッシャーに適切なフィードバックを提供するため

当社では、不快なコンテンツに関するあらゆる苦情に対応する苦情担当者を任命しています。

不快なコンテンツに関する苦情は、上記の電子メール アドレスに電子メールで苦情担当者に送信するようお願いします。また、苦情を申し立てる際には、以下の詳細を提供するようお願いします。

さまざまな雑誌、書籍、ニュース、雑誌および出版物関連コンテンツ (総称して「出版物」と呼ばれます) を注文、購読、配信を受け取り、これらの出版物のデジタル版を配信する機能を提供するアプリ

c.また、パーソナライズされた推奨事項を作成するために、アプリケーションの使用に関連する情報も収集します。お客様がサードパーティのアカウント資格情報を当社に提供した場合、お客様がそのような送信を許可した場合、それらのアカウント内の一部のコンテンツおよび / または情報(以下「サードパーティのアカウント情報」) がお客様のアカウントに送信される可能性があること、およびそのサードパーティのアカウントが当社のアカウントに送信される可能性があることを理解したものとします。サービスに送信される情報は、本ポリシーの対象となります。

 f.当社が収集する個人情報により、当社はお客様のリクエストに対応し、当社の製品とサービスを改善し、お客様に表示される広告とコンテンツをカスタマイズし、新製品についてお客様に連絡することができます。

は、2011 年の設立以来 9,000 万人を超えるユーザーがおり、40 以上のカテゴリと 60 以上の言語にわたる数千の雑誌や新聞を擁する、世界最大かつ急速に成長しているセルフサービスのクロスプラットフォーム デジタル ニューススタンドです。ニューヨークに本社を置く Magzter は、アムステルダム、ロンドン、メキシコシティ、チェンナイ、ムンバイ、ニューデリー、バンガロール、シンガポールに現地拠点を置いており、間もなく他の国にも拡大する予定です。 2011 年 6 月に世界的起業家であるギリッシュ ラムダス氏とビジェイ ラダクリシュナン氏によって設立された Magzter は、世界中の雑誌や新聞の出版社が自社のタイトルのデジタル版を作成し、世界中の消費者に配信できるようにします。

 n.また、ユーザーが当社の利用規約を遵守していることを確認するために、使用状況情報も使用されます。たとえば、ユーザーの使用状況情報は、ユーザーが雑誌やその他のコンテンツを許可された回数、または許可された数のデバイスにのみダウンロードしていることを確認するのに役立ちます。

これにより、デジタル読者は月額購読料で 9,000 以上の雑誌や新聞に無制限にアクセスできるようになります。 Magzter はまた、アプリ向けの革新的な ezRead 2.0 機能により、世界最大の記事数を誇ります。これにより、スマートフォンや小さな画面のモバイル ユーザーは、本来の楽しみ方で雑誌コンテンツを楽しむことができます。読みやすく、素晴らしいビデオと高解像度の写真が付いています。

BioTecNika - December 2018

BioTecNika - December 2018

この問題で

BioTecNika Magazine Description: